![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1528602
¼öµÎÁõ ¼ÇÆ® ½ÃÀå : Á¦Ç°º°, ½Ã¼úº°, ¿¬·É´ëº°, ÃÖÁ¾ ¿ëµµº°, ¼¼°è ¿¹Ãø(2024-2032³â)Hydrocephalus Shunt Market - Product (Valves [Adjustable, Fixed], Catheters), Procedure (Ventriculoperitoneal, Lumboperitoneal, Ventriculoatrial, Ventriculopleural), Age Group (Pediatric, Adult), End Use (Hospitals, ASCs), Global Forecast (2024 - 2032) |
¼öµÎÁõ ¼ÇÆ® ½ÃÀå ±Ô¸ð´Â ¼öµÎÁõ ¹× °ü·Ã ½Å°æ ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ÈûÀÔ¾î 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 3.5%ÀÇ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º¸°í¼¿¡ µû¸£¸é Àü ¼¼°èÀûÀ¸·Î ¿¬°£ ¾à 40¸¸ ¸íÀÇ ¾î¸°À̰¡ ¼öµÎÁõ Áø´ÜÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¼öµÎÁõÀº ¼±Ãµ¼º ¹× ÈÄõ¼º ¸ðµÎ Áõ°¡ Ãß¼¼¿¡ ÀÖÀ¸¸ç, ƯÈ÷ ¼Ò¾Æ ¹× ³ëÀÎÀÇ ¼öµÎÁõ Áõ°¡´Â ¼ÇÆ® ÀåÄ¡¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. Áø´Ü ±â¼úÀÇ ¹ßÀü°ú ÀÇ·áÁøÀÇ ÀÎ½Ä °³¼±µµ Á¶±â ¹ß°ß ¹× Á¶±â Ä¡·á¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
ÃֽмöµÎÁõ ¼ÇÆ®´Â »ýü ÀûÇÕ¼º, ½Å·Ú¼º ¹× »ç¿ë ÆíÀǼºÀ» Çâ»ó½Ã۱â À§ÇØ Àç·á¿Í ¸ÞÄ¿´ÏÁòÀÌ °³¼±µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ÇÁ·Î±×·¡¹Ö °¡´ÉÇÑ ¹ëºê¿Í ¿ø°Ý ¸ð´ÏÅ͸µ ±â´É°ú °°Àº Çõ½ÅÀûÀÎ ±â¼úÀº ȯÀÚÀÇ ¿¹ÈÄ¿Í ÆíÀǼºÀ» °³¼±ÇÏ¿© ÀÇ·á Àü¹®°¡¿¡°Ô ´õ¿í ¸Å·ÂÀûÀÎ Àåºñ°¡ µÇ°í ÀÖ½À´Ï´Ù. ¼ÇÆ® ±â¼ú °³¼±°ú ÀÀ¿ë ºÐ¾ß È®´ë¸¦ À§ÇÑ ¿¬±¸°³¹ß ³ë·ÂÀÌ Áõ°¡ÇÏ¸é¼ ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
»ê¾÷Àº Á¦Ç° À¯Çü, ½Ã¼ú À¯Çü, ¿¬·É´ë, ÃÖÁ¾ ¿ëµµ, Áö¿ªÀ¸·Î ±¸ºÐµË´Ï´Ù.
Á¦Ç°º°·Î º¸¸é ¼öµÎÁõ ¼ÇÆ® ½ÃÀåÀº 2032³â±îÁö ¼öµÎÁõ Ä«Å×ÅÍ ºÎ¹®ÀÌ ±× È¿°ú¿Í ±â´É¼ºÀ¸·Î ÀÎÇØ Å« ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, Ä«Å×ÅÍ ±â¼úÀÇ ¹ßÀüÀ¸·Î Àç·áÀÇ °³¼±°ú µðÀÚÀÎ Çõ½ÅÀ¸·Î »ýü ÀûÇÕ¼ºÀÌ Çâ»óµÇ°í ÇÕº´Áõ À§ÇèÀÌ °¨¼ÒÇÔ¿¡ µû¶ó Ä«Å×ÅÍ Ã¤ÅÃÀÌ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿äÃߺ¹° ¼ÇÆ®´Â ±âÁ¸ÀÇ ³ú½Çº¹° ¼ÇÆ®°¡ ÀûÇÕÇÏÁö ¾ÊÀº ÁúȯÀ» °ü¸®ÇÏ´Â µ¥ È¿°úÀûÀ̱⠶§¹®¿¡ 2024³âºÎÅÍ 2032³â±îÁö Å« ¼öÀÍÀ» âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿äÃߺ¹¸·(LP) ¼ÇÆ®´Â ³úô¼ö¾×À» Ç㸮¿¡¼ º¹°À¸·Î ¿ìȸ½Ãų ¼ö ÀÖ¾î ü¾× °ü¸®¿¡ ´ëÇÑ ¶Ç ´Ù¸¥ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇϸç, º¹ÀâÇÑ È¯Àڵ鿡°Ô À¯¿ëÇÑ ´ë¾ÈÀÌ µÇ°í ÀÖ½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¼öµÎÁõ ¼ÇÆ® »ê¾÷Àº ÀÇ·á ÀÎÇÁ¶óÀÇ ±Þ¼ÓÇÑ °³¼±°ú ÀÇ·á ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡·Î ÀÎÇØ 2032³â±îÁö »ó´çÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀÔ´Ï´Ù. ¿©·¯ ±¹°¡°¡ ÀÇ·á ½Ã½ºÅÛÀ» °ÈÇÏ°í °í±Þ Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇÔ¿¡ µû¶ó ¼öµÎÁõ ȯÀÚ¸¦À§ÇÑ Àü¹® Ä¡·á¿¡ ´õ ½±°Ô Á¢±Ù ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã¼³À» °³¼±Çϰí Ä¡·á ºñ¿ëÀ» º¸Á¶Çϱâ À§ÇÑ Á¤ºÎÀÇ ³ë·Â°ú ÀÇ·á Á¤Ã¥µµ ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
Hydrocephalus shunt market size is likely to register a 3.5% CAGR from 2024-2032 driven by the increasing prevalence of hydrocephalus and related neurological conditions. As per reports, annually around 400,000 children worldwide are diagnosed with hydrocephalus. The rising incidence of hydrocephalus, including both congenital and acquired forms, particularly in pediatric and elderly populations, is boosting the demand for shunt devices. Advances in diagnostic techniques and increased awareness among healthcare providers will also contribute to earlier detection and treatment.
Modern hydrocephalus shunts feature enhanced materials and advanced mechanisms for better bio-compatibility, reliability, and ease of use. Innovations, such as programmable valves and remote monitoring capabilities are also offering improved patient outcomes and convenience, making these devices more attractive to healthcare professionals. Increased R&D efforts aimed at refining shunt technologies and expanding applications will add to the market growth.
The industry is segmented into product, procedure type, age group, end-use, and region.
Based on product, the hydrocephalus shunt market from the hydrocephalus catheters segment will record a significant growth rate through 2032 due to their effectiveness and functionality. Advancements in catheter technology, such as improved materials and design innovations are also enhancing bio-compatibility and reducing the risk of complications, further contributing to their increasing adoption.
Hydrocephalus shunt market from the lumboperitoneal procedure type segment is poised to generate substantial revenue between 2024 and 2032 owing to their effectiveness in managing conditions where traditional ventriculoperitoneal shunts are less suitable. The ability of lumboperitoneal (LP) shunts to divert cerebrospinal fluid from the lumbar region to the peritoneal cavity provides an alternative approach to fluid management, making them a valuable option in complex cases.
Asia Pacific hydrocephalus shunt industry size will grow at a substantial CAGR through 2032 attributed to the rapidly improving healthcare infrastructure and increased investments in medical technologies. As several countries are enhancing their healthcare systems and expanding access to advanced treatments, there is greater availability of specialized care for hydrocephalus patients. Government initiatives and healthcare policies aimed at improving medical facilities and subsidizing treatment costs will also help in driving the regional market growth.